Long-term follow-up of pharmacokinetics (PK) and immunogenicity of the anti–PD-1 antibodies nivolumab (Nivo) and pembrolizumab (Pembro) in real-world practice.

Masahide Fukudo,Kazuto Mishima,Norihisa Kimura,Yuichiro Shinden,Takaaki Sasaki,Shunsuke Okumura,Yoshinobu Ohsaki,Jiro Uehara,Akemi Yamamoto,Gaku Tamaki,Hidehiro Kakizaki,Kan Kishibe,Miki Takahara,Tatsuya Hayashi,Yasuaki Harabuchi,Tatsuya Shonaka,Kimiharu Hasegawa,Takashi Ono,Yoshikazu Tasaki

Long-term follow-up of pharmacokinetics (PK) and immunogenicity of the anti–PD-1 antibodies nivolumab (Nivo) and pembrolizumab (Pembro) in real-world practice.

2019

Masahide Fukudo
Kazuto Mishima
Norihisa Kimura
Yuichiro Shinden
Takaaki Sasaki
Shunsuke Okumura
Yoshinobu Ohsaki
Jiro Uehara
Akemi Yamamoto
Gaku Tamaki
Hidehiro Kakizaki
Kan Kishibe
Miki Takahara
Tatsuya Hayashi
Yasuaki Harabuchi
Tatsuya Shonaka
Kimiharu Hasegawa
Takashi Ono
Yoshikazu Tasaki

3120Background: The PD-1 blockers Nivo and Pembro are widely used to treat patients (pts) with various types of cancer, but their PK and immunogenicity have not been adequately characterized in cli...

Keywords:

Nivolumab
Immunogenicity
Pathology
Antibody
Pembrolizumab
Oncology
Pharmacokinetics
Internal medicine
Medicine
anti pd 1
Cancer
long term follow up

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations